1-12 of 12
Wei Tian
Close
Sort by
Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Zhe Zhuang, Ying Tian, Hong Yu, Lei Shi, Wei-wei Tian, Qinhua Liu, Dongmei Zou, Fei Dong, Yanping Ma, Ru Feng, Shuangjiao Liu, Hui Liu, Hongmei Jing, Wanling Sun, Liangming Ma, Li Bao, Rong Fu, Yin Wu, Chen Wenming, Junling Zhuang
Journal: Blood
Blood (2022) 140 (Supplement 1): 12637–12639.
https://doi.org/10.1182/blood-2022-169057
Published: 2022
Journal Articles

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Zhe Zhuang, Lei Shi, Ying Tian, Dongmei Zou, Ru Feng, Fei Dong, Yanping Ma, Hong Yu, Wei-wei Tian, Shuangjiao Liu, Liangming Ma, Rong Fu, Hongmei Jing, Hui Liu, Wanling Sun, Chen Wenming, Yin Wu, Li Bao, Junling Zhuang
Journal: Blood
Blood (2021) 138 (Supplement 1): 4728.
https://doi.org/10.1182/blood-2021-149502
Published: 2021
Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Zhe Zhuang, Ying Tian, Wei-wei Tian, Hong Yu, Dongmei Zou, Qinhua Liu, Lei Shi, Fei Dong, Yanping Ma, Ru Feng, Shuangjiao Liu, Hui Liu, Hongmei Jing, Li Bao, Wanling Sun, Rong Fu, Liangming Ma, Chen Wenming, Yin Wu, Junling Zhuang
Journal: Blood
Blood (2021) 138 (Supplement 1): 4766.
https://doi.org/10.1182/blood-2021-152542
Published: 2021
Journal Articles

Consistent Efficacy Demonstrated By Avatrombopag in Immune Thrombocytopenia (ITP) Regardless of the Number of Lines of Prior ITP Treatment

Morey Blinder, MD, Michael Vredenburg, PhD, Wei Tian, PhD, Brian Jamieson, MDBA, Keith R McCrae, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-136585
Published: 2020
Journal Articles

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Wei Tian, PhD, Brian Jamieson, MDBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 10.
https://doi.org/10.1182/blood-2020-141290
Published: 2020
Journal Articles

Efficacy Analyses from the Immune Thrombocytopenia (ITP) Clinical Development Program for Avatrombopag: Comparisons with Placebo and Eltrombopag

Michael D Tarantino, MD, Michael Vredenburg, PhD, Wei Tian, PhD, Brian Jamieson, MDBA, Kashyap B Patel, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-142788
Published: 2020
Journal Articles

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Hanny Al-Samkari, MD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2356.
https://doi.org/10.1182/blood-2019-131215
Published: 2019
Journal Articles

Platelet Response to Avatrombopag in Patients with Chronic Immune Thrombocytopenia: Additional Analyses from a Phase 3 Study and Its Extension

Srikanth Nagalla, MBBS,MS, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1071.
https://doi.org/10.1182/blood-2019-130963
Published: 2019
Journal Articles

Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials

James B. Bussel, MD, Lee F. Allen, MD PhD, Wei Tian, PhD, David J. Kuter, MD DPhil
Journal: Blood
Blood (2018) 132 (Supplement 1): 3740.
https://doi.org/10.1182/blood-2018-99-116873
Published: 2018
Journal Articles

Serum Platelet Factor 4 Is a Promising Therapeutic Response and Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma

Ju Bai, Aili He, Wanggang Zhang, Yun Yang, Jianli Wang, Pengyu Zhang, Yang Zhang, Lei Zhang, Liufang Gu, Jin Wang, Rui Shi, Xin Meng, Wei Tian, Xiaman Wang, Xiaoru Lei
Journal: Blood
Blood (2014) 124 (21): 2004.
https://doi.org/10.1182/blood.V124.21.2004.2004
Published: 2014
Journal Articles

FcγR-stimulated activation of the NADPH oxidase: phosphoinositide-binding protein p40 phox regulates NADPH oxidase activity after enzyme assembly on the phagosome

Wei Tian, Xing Jun Li, Natalie D. Stull, Wenyu Ming, Chang-Il Suh, Sarah A. Bissonnette, Michael B. Yaffe, Sergio Grinstein, Simon J. Atkinson, Mary C. Dinauer
Journal: Blood
Blood (2008) 112 (9): 3867–3877.
https://doi.org/10.1182/blood-2007-11-126029
Published: 2008
Includes: Multimedia, Supplemental data
Journal Articles

The Phosphoinositide-Binding Protein p40 phox Regulates NADPH Oxidase Activation Rather Than Assembly during FcγIIA Receptor-Induced Phagocytosis.

Wei Tian, PhD, Xing Jun Li, MD, PhD, Natalie D. Stull, Chang-Il Suh, PhD, Sergio Grinstein, PhD, MIchael B. Yaffe, MD, PhD, Simon J. Atkinson, PhD, Mary C. Dinauer, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 678.
https://doi.org/10.1182/blood.V108.11.678.678
Published: 2006